参考文献/References:
[1] Boutros C,Tarhini A,Routier E,et al.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J].Nat Rev Clin Oncol,2016,13(8):473-486.DOI:10.1038/nrclinonc.2016.58.
[2] Champiat S,Lambotte O,Barreau E,et al.Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper[J].Ann Oncol,2016,27(4):559-574.DOI:10.1093/annonc/mdv623.
[3] Byun DJ,Wolchok JD,Rosenberg LM,et al.Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J].Nat Rev Endocrinol,2017,13(4):195-207.DOI:10.1038/nrendo.2016.205.
[4] Marathe PH,Gao HX,Close KL.American Diabetes Association Standards of Medical Care in Diabetes 2017[J].J Diabetes,2017,9(4):320-324.DOI:10.1111/1753-0407.12524.
[5] Dillard T,Yedinak CG,Alumkal J,et al.Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis:serious immune related adverse events across a spectrum of cancer subtypes[J].Pituitary,2010,13(1):29-38.DOI:10.1007/s11102-009-0193-z.
[6] Nallapaneni NN,Mourya R,Bhatt VR,et al.Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash[J].J Natl Compr Canc Netw,2014,12(8):1077-1081.DOI:10.6004/jnccn.2014.0105.
[7] Zhao C,Tella SH,Del Rivero J,et al.Anti-PD-L1 Treatment Induced Central Diabetes Insipidus[J].J Clin Endocrinol Metab,2018,103(2):365-369.DOI:10.1210/jc.2017-01905.
[8] Gunawan F,George E,Roberts A.Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies[J].Endocrinol Diabetes Metab Case Rep,2018,2018:17-0146.DOI:10.1530/EDM-17-0146.
[9] Torino F,Corsello SM,Salvatori R.Endocrinological side-effects of immune checkpoint inhibitors[J].Curr Opin Oncol,2016,28(4):278-287.DOI:10.1097/CCO.0000000000000293.
[10] Yamazaki N,Kiyohara Y,Uhara H,et al.Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma[J].Cancer Chemother Pharmacol,2015,76(5):997-1004.DOI:10.1007/s00280-015-2873-x.
[11] Tsiogka A,Jansky GL,Bauer JW.Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma[J].Melanoma Res,2017,27(5):524-525.DOI:10.1097/CMR.0000000000000384.
[12] Kochupurakkal NM,Kruger AJ,Tripathi S,et al.Blockade of the programmed death-1(PD1)pathway undermines potent genetic protection from type 1 diabetes[J].PLoS One,2014,9(2):e89561.DOI:10.1371/journal.pone.0089561.
[13] Hanafusa T,Imagawa A.Fulminant type 1 diabetes:a novel clinical entity requiring special attention by all medical practitioners[J].Nat Clin Pract Endocrinol Metab,2007,3(1):36-45; quiz 2p following 69.DOI:10.1038/ncpendmet0351.
[14] Lowe JR,Perry DJ,Salama AK,et al.Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy[J]J Immunother Cancer,2016,4:89.DOI:10.1186/s40425-016-0196-z.
[15] Chae YK,Chiec L,Mohindra N,et al.A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes[J].Cancer Immunol Immunother,2017,66(1):25-32.DOI:10.1007/s00262-016-1913-7.
[16] Smith-Cohn MA,Gill D,Voorhies BN,et al.Case report:pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma[J].Immunotherapy,2017,9(10):797-804.DOI: 10.2217/imt-2017-0042.
[17] Aleksova J,Lau PK,Soldatos G.Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma[J].BMJ Case Rep,2016,2016:bcr2016217454.DOI:10.1136/bcr-2016-217454.
[18] Brahmer JR,Lacchetti C,Schneider BJ,et al.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy:American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(17):1714-1768.DOI:10.1200/JCO.2017.77.6385.